BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 20880116)

  • 1. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic score including gene mutations in chronic myelomonocytic leukemia.
    Itzykson R; Kosmider O; Renneville A; Gelsi-Boyer V; Meggendorfer M; Morabito M; Berthon C; Adès L; Fenaux P; Beyne-Rauzy O; Vey N; Braun T; Haferlach T; Dreyfus F; Cross NC; Preudhomme C; Bernard OA; Fontenay M; Vainchenker W; Schnittger S; Birnbaum D; Droin N; Solary E
    J Clin Oncol; 2013 Jul; 31(19):2428-36. PubMed ID: 23690417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
    Pich A; Riera L; Sismondi F; Godio L; Davico Bonino L; Marmont F; Francia di Celle P
    J Clin Pathol; 2009 Sep; 62(9):798-801. PubMed ID: 19734476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders.
    Caudill JS; Sternberg AJ; Li CY; Tefferi A; Lasho TL; Steensma DP
    Br J Haematol; 2006 Jun; 133(6):638-41. PubMed ID: 16704439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
    Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
    Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
    Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
    Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.
    Gelsi-Boyer V; Trouplin V; Adélaïde J; Aceto N; Remy V; Pinson S; Houdayer C; Arnoulet C; Sainty D; Bentires-Alj M; Olschwang S; Vey N; Mozziconacci MJ; Birnbaum D; Chaffanet M
    BMC Cancer; 2008 Oct; 8():299. PubMed ID: 18925961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 20. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
    Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
    Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.